For a sponsor running a trial across the US and Europe, most of the delay lives in the seams between vendors, sites, and regions. That was the thread running through a recent Castor LinkedIn Live, hosted by Derk Arts, Founder and CEO of Castor, with Joel Morse, CEO and Co-Founder of Curavit Clinical Research, and Joel White, Owner of Marketcap Consulting and an independent analyst who follows the clinical research industry closely. The occasion was Curavit’s acquisition of Lindus Health’s CRO assets, which brings US and European trial delivery under one roof while Lindus turns its focus to drug development. What followed was a direct conversation about where cross-Atlantic trials lose time, and where technology and AI realistically fit.
What the conversation covered
The headline is consolidation, but the substance was about removing the seams that slow cross-Atlantic trials. Joel M. walked through how the two teams merged, roughly forty to fifty people across the UK, Europe, and the US, in about two months, and why he structured it as a stock-for-assets deal rather than the all-cash structure more common in recent deals. Aligning incentives, he explained, keeps everyone invested in the same outcome.
The most useful thread for anyone choosing vendors was about technology. Several CROs have tried to become full-service and own their entire tech stack at the same time, a pattern Joel W. has followed closely. Building software that sponsors actually adopt is genuinely hard, especially when the market already runs strong, embedded tools.
“If you’re asking a sponsor to use you as a CRO and require them to use your software, that’s tough in this market with so much embedded great technology.”Joel White, Owner, Marketcap Consulting
Curavit’s answer was to build for what is uniquely theirs and connect to the rest.
“…build a platform that we call Stratus… and then we would API into what I call standard clinical technology, like the great technology that Castor creates.”Joel Morse, CEO and Co-Founder, Curavit Clinical Research
The other throughline was speed and certainty. Joel M. described a decentralized trial where Curavit enrolled half the participants in four months, while ten physical sites needed another full year to enroll the rest. Sponsors want endpoint quality and safety, and they also want assurance on timing and budget. Controlling recruitment is how you promise it.
On AI, all three landed in the same place. The change is real and it arrives steadily, moving out from document and safety workflows toward data extraction and, over time, monitoring, which is where our own work on Castor Catalyst is focused. The gating factor is not capability. It is trust, and trust has to be earned.
“With AI comes an even greater… distrust. We have… five years of education and trust building ahead of us.”Derk Arts, Founder and CEO, Castor
There is a subtlety in how the technology fits together that is worth drawing out. When a CRO builds its own tools and connects them to the platform underneath, that platform is not the interchangeable part. It is the layer everything else has to trust and depend on, which is a harder thing to be, not an easier one. The teams that get this right own what is genuinely theirs and connect the rest to a core they can rely on. That core is not a commodity. It is the part that has to be right.
What’s in the full recording
The conversation went well beyond this summary. A few moments worth your time:
- Joel M. on the deal mechanics, a stock-for-assets swap that kept both companies invested in the outcome (16:27)
- Joel W. on the other CROs that have made the same move, and the one signature they shared (08:22)
- The decentralized enrollment story: half the participants in four months (12:49)
- Joel W. on a 1996 filing that named source-document verification as the number one problem to solve, and how long real change takes (33:59)
- How Curavit’s stack integrates with the EDC on a live device trial, from an audience question (42:15)
- The economics of digital patient recruitment, and what a Meta-sourced enrollment actually costs (45:31)
One practical takeaway for your own program. When you weigh a CRO or a platform, separate what each side should genuinely own from what should simply connect, and pressure-test your recruitment timeline early, because that is where speed and certainty are won or lost.
Watch the full conversation on the LinkedIn Live event page. This swaps to the castoredc.com on-demand page once it is live. It is worth an hour for anyone weighing how to run cleaner trials across the US and Europe, and where technology and AI realistically fit.
FAQ
What did Curavit acquire from Lindus Health?
Curavit acquired Lindus Health’s CRO assets in an asset purchase, bringing US and European trial delivery under one roof. Lindus is now focusing on drug development as Lindus Therapeutics. Roughly forty to fifty people moved across, and Joel M. said the deal closed in about two months.
Does running a trial through one CRO across the US and Europe remove cross-Atlantic friction?
That was the central question of the session. The panel’s view was that unifying delivery helps, but the real gain comes from controlling recruitment timelines and budget through the delivery model. Sponsors still want endpoint quality and safety, and they also want assurance on timing and cost.
Where does AI fit in clinical research delivery today?
The consensus was evolution rather than revolution. The frontier is moving out from document and safety workflows toward data extraction and, over time, monitoring. Castor Catalyst is focused on that extraction and review work. AI here is AI-driven work with a human in the loop, and the gating factor is trust, which has to be earned.
